Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Immix Biopharma, Inc. has successfully closed an underwritten registered offering, raising approximately $93.7 million through the sale of common stock and pre-funded warrants, with significant participation from leading U.S. biotechnology institutional investors and mutual funds [1][2]. Financing Details - The offering consisted of 19,117,646 shares of common stock priced at $5.10 per share and pre-funded warrants to purchase 490,196 shares at $5.09 each, resulting in net proceeds of about $93.7 million after expenses [1]. - Morgan Stanley served as the sole book-running manager, with Citizens Capital Markets and Mizuho acting as co-managers for the offering [2]. Regulatory Information - The securities were offered under a "shelf" registration statement on Form S-3, which was filed with the SEC and became effective in January 2023 [3]. Company Overview - Immix Biopharma, Inc. is recognized as a global leader in treating relapsed/refractory AL Amyloidosis, a severe disease characterized by the immune system producing toxic light chains that can lead to organ failure [5]. - The company's lead candidate, NXC-201, is a CAR-T cell therapy designed to target and eliminate the source of toxic light chains, currently being evaluated in a U.S. multi-center study [5].